Cabozantinib Fails In the Phase III COMET-1 Trial

The pharmaceutical company Exelixis has announced that their experimental treatment, cabozantinib has failed the Phase III clinical trial for men with metastatic castration-resistant prostate cancer (mCRPC). In the trial the experimental treatment cabozantinib was compared to the drug prednisone. In the trial known as COMET-1, Cabozantinib, a tyrosine kinase inhibitor, did not meet its primary [...]

On the Horizon – Targeting Bones in the Treatment of Advanced Prostate Cancer

Osteoblasts and osteoclasts are the process that the body uses to breakdown old bone and then to rebuild it with new bone. c-Met is a tyrosine kinase expressed by osteoblasts and osteoclasts, and overexpressed by prostate cancer cells. This over expression leads to the eventual development of bone metastases. The experimental treatment known as Cabozantinib [...]

On the Horizon – CABOZANTINIB IN MEN WITH ADVANCED PROSTATE CANCER: RESULTS OF A PHASE II RANDOMIZED TRIAL

Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. It is designed to target the men with castration resistant prostate cancer (CRPC). Results from a phase II randomized discontinuation trial with an expansion cohort of XL184 have recently been released. The trial included men [...]

On the Horizon – Cabozantinib for the Treatment of Bone Mets in Men with Advanced Prostate Cancer

According to researchers from the University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan men with advanced prostate cancer experienced significant and rapid positive effects from an investigational treatment known as cabozantinib. In a n article published online in the Journal of Clinical Oncology (Nov. 19, 2012) approximately two-thirds of men who were treated with [...]

On the Horizon: Cabozantinib (XL184) Phase II Trial in Men with Castrate Resistant Prostate Cancer

We are again looking at a potentially new block buster drug to treat men with advanced prostate cancer whose cancer has become castrate resistant. This potential drug seems to have clinical activity in both soft tissue and bone mets. This investigational drug is called Cabozantinib (XL184). It is a tyrosine kinase inhibitor with activity against [...]

Cabozantinib, Promising, Still Controversial For the Treatment of Bone Mets in Prostate Cancer

Cabozantinib (cabo), has many of us prostate cancer survivor, educators and researchers simply scratching their heads. In trials, Cabozantinib demonstrated what some people have characterized as mind boggling activity against bone metastases. In trials the drug led to partial or complete resolution of bone scans in a substantial portion of patients with cancer, including prostate, [...]

ASCO 2011: Phase II Cabozantinib Trial in Patients with Advanced Solid Tumors and Bone Metastases

Data from the recent ASCO conference on a phase II study of cabozantinib (XL184) in patients with advanced solid tumors, including prostate cancer, demonstrates that the investigational treatment has activity in both bone and soft tissue. This study evaluated the efficacy and safety of cabozantinib compared to placebo in 9 different solid tumor types including [...]

Combining and Sequencing the New Prostate Cancer Drugs, Can It Improve Treatment Outcomes? – On the Horizon

There is good reason for guarded optimism among men with advanced prostate cancer. Over the last 2 years we have seen some significant movement with the development of new drugs and treatments for men with advanced prostate cancer. All of these drugs have demonstrated a survival advantage in their clinical trials. Each of the agents [...]

Go to Top